For years a particular model held parts of the aesthetics market together. A non-prescribing injector would assess a patient, send the details to a prescriber who had never met them, and receive a prescription or a direction to administer in return. It was efficient, it was common, and it is no longer defensible under the guidance of any of the four regulators that govern prescribing. The last pieces of that framework fell into place in 2025, when the NMC and the GPhC both tightened their positions, aligning with rules the GMC and the GDC had already set.
This article sets out what each regulator now expects, where the words come from, and what it means for a clinic that has relied on a remote prescriber. It is written for doctors, dentists, independent prescribing nurses, midwives and pharmacists, and for clinic owners whose business model depends on how prescribing is arranged.
What remote prescribing means in aesthetics
Remote prescribing, in this context, means prescribing a prescription-only medicine such as botulinum toxin without having physically examined the patient. It covers prescribing by telephone, by video call, through an online questionnaire, or at the request of another person who has seen the patient when the prescriber has not. The distinction that matters is not the technology but the examination: the regulators are concerned with whether the person who takes clinical and legal responsibility for the prescription has personally assessed the patient. Botulinum toxin is a prescription-only medicine, so it must be prescribed by an appropriate prescriber before it can be administered, and that is the point at which these rules bite.
What the GMC expects of doctors
The GMC's position is the clearest and the longest standing. Its guidance on good practice in prescribing states that "you must carry out a physical examination of patients before prescribing non-surgical cosmetic medicines, such as Botox, Dysport, Vistabel or other injectable cosmetic medicines", and concludes, in terms, that "you must not prescribe these medicines remotely." The guidance for doctors who offer cosmetic interventions puts the same rule a different way, saying a doctor "must not therefore prescribe these medicines by telephone, video link, online or at the request of others for patients you have not examined."
That last phrase, "at the request of others for patients you have not examined", is the one that ends the remote-signer model for doctors. A doctor who prescribes on the basis of a form completed by an injector, without examining the patient, is doing exactly what the guidance prohibits. The responsibility for the decision sits with the prescriber, and it cannot be discharged by relying on someone else's assessment.
What the NMC now requires of nurses and midwives
The NMC changed its position in 2025 after a consultation it opened in August 2024. From 1 June 2025, independent nurse and midwife prescribers must carry out a face-to-face consultation and clinical assessment before prescribing any product used for an elective non-surgical cosmetic procedure. The NMC states that "it is not appropriate to prescribe medicinal products for these purposes by remote methods", and lists telephone, email, online, video and prescribing through a third party among those remote methods. The requirement covers the initial consultation and any follow-ups, not only the first appointment.
The NMC also makes two practical points that clinics often miss. It treats a patient specific direction as the lawful mechanism for these procedures, which means the prescriber assesses the patient and then issues a direction for a named individual, rather than a general protocol. And it notes that nurse and midwife independent prescribers are not eligible to hold prescription-only medicine stock for this purpose. Together these close off the workarounds that grew up around remote prescribing.
Interactive
What each regulator says
Doctors. A physical examination is required before prescribing injectable cosmetic medicines, and the guidance states doctors must not prescribe them remotely or at the request of others for patients they have not examined. This has been the GMC's settled position for years.
Nurses and midwives. From 1 June 2025, independent nurse and midwife prescribers must carry out a face-to-face consultation before prescribing non-surgical cosmetic medicines. Remote methods are not appropriate, and a patient specific direction is the lawful route.
Pharmacists. Guidance updated in April 2025 says a physical examination must take place and that it is not appropriate to carry out a remote consultation for non-surgical cosmetic products. Pharmacist supplementary prescribers cannot prescribe these products at all.
Dentists. The GDC states that dentists must not remote prescribe for non-surgical cosmetic procedures, including the prescription or administration of Botox. Among dental professionals, only dentists hold independent prescribing rights.
What the GPhC expects of pharmacists
The GPhC updated its guidance for pharmacist prescribers in April 2025. On non-surgical cosmetic products, which it names as including botulinum toxin, it requires that prescribing happens only after a physical examination of the person, and it states that "it is not appropriate to carry out a remote consultation for non-surgical cosmetic products." Its section on online prescribing gives non-surgical cosmetic products as the example of medicines that are not suitable to be prescribed online.
There is an additional limit specific to pharmacy. A pharmacist independent prescriber may prescribe within their competence, but a pharmacist supplementary prescriber "cannot prescribe veterinary medicines or non-surgical cosmetic products" at all. A clinic that uses a pharmacist prescriber should therefore confirm which kind of prescriber it is working with, because the two have different scope.
What the GDC expects of dentists
The GDC's guidance on prescribing medicines applies to dentists who prescribe for cosmetic purposes. It states that dentists "must not remote prescribe (for example, via telephone, email, or a website) for non-surgical cosmetic procedures, such as the prescription or administration of Botox or injectable cosmetic medicinal products." As a general principle it also says remote prescribing should only be used "if there is no other viable option and it is in their best interests", which is plainly not the case for an elective cosmetic treatment. Among dental professionals, the GDC notes that only dentists hold independent prescribing rights, so the prescribing decision cannot be passed to a dental nurse or therapist.
The lawful model, and the one that is not
The common thread across all four regulators is simple to state. The prescriber must assess the patient in person before prescribing, and the responsibility for the decision stays with them. From that assessment they may write a prescription, or issue a patient specific direction for a named patient to be treated by a trained injector. What they may not do is prescribe for a patient they have not examined, however the information reaches them. A patient group direction, which some clinics ask about, cannot be used for botulinum toxin administered for cosmetic purposes, so it is not an alternative route.
Check your understanding
A clinic's injector is a registered nurse who is not a prescriber. She assesses each patient, then sends the details to an online prescriber who never meets them and returns a prescription. Is this compliant?
This is the remote-prescribing model the regulators have closed. The prescriber must personally assess the patient in person before prescribing a non-surgical cosmetic medicine. It does not matter that a prescriber signs, or that the injector is experienced. The GMC, NMC, GPhC and GDC each require an in-person assessment by the prescriber, so the clinic needs a prescriber who sees the patient.
What this means for clinics that use a remote prescriber
For a clinic that has built its service around a remote prescriber, the practical consequence is that the prescriber has to be present, in person, for the assessment of each new patient and at the points where a further prescribing decision is needed. This is more than an administrative change, because it affects staffing, cost and the way appointments are booked. It is also now a fitness-to-practise issue for the prescriber, whose registration is at risk if they prescribe outside their regulator's guidance, as well as a governance issue for the clinic that arranges the service.
Common assumptions
Tap each card to compare the assumption with the rule.
What to do in clinic
- Map how prescribing happens now. For every treatment that uses a prescription-only medicine, write down who prescribes, whether they examine the patient in person, and whether a patient specific direction is used. Be honest about any remote arrangement.
- Make the prescriber present for the assessment. Arrange for the prescriber to assess each new patient in person before prescribing, and at any point where a new prescribing decision is needed. A video call does not meet the standard for these medicines.
- Use a patient specific direction, not a group direction. Where a trained injector administers after the prescriber's assessment, use a patient specific direction for the named patient. A patient group direction cannot be used for cosmetic botulinum toxin.
- Check the prescriber's category. Confirm whether a pharmacist prescriber is an independent or supplementary prescriber, because supplementary prescribers cannot prescribe non-surgical cosmetic products at all.
- Record the assessment and consent. Document the in-person assessment, the discussion of material risks and reasonable alternatives, and the prescribing decision, so the record shows the lawful route was followed. Our guidance on what to write in the notes after an aesthetic consultation sets out the standard.
These changes sit alongside the wider tightening of cosmetic regulation, including the consultation on restricting high-risk procedures and the sourcing and consent duties highlighted by the botulism cases linked to unlicensed toxin. The consent standard that applies to the in-person assessment is the one set by Montgomery, which turns on the material risks and reasonable alternatives for the individual patient. For clinics that want an independent view of how their prescribing, consent and records would stand up, our consent and governance review covers exactly these arrangements, and the free Medicolegal Readiness Score gives a quick first indication. The product-specific duties for toxin are set out on our botulinum toxin consent page.
Frequently asked questions
Not for cosmetic use. The regulators require a physical examination before prescribing injectable cosmetic medicines, and they list video link among the remote methods that are not appropriate. A video call does not meet the standard.
No. A trained injector who is not a prescriber can administer the treatment, provided the prescriber has assessed the patient in person and issued a prescription or a patient specific direction for that named patient. What is not allowed is the prescriber signing without having examined the patient.
A patient specific direction is a written instruction from a prescriber to administer a medicine to a named patient the prescriber has assessed. A patient group direction allows administration to a group of patients without an individual prescription, but it cannot be used for botulinum toxin given for cosmetic purposes.
The NMC requirement for a face-to-face consultation before prescribing non-surgical cosmetic medicines took effect on 1 June 2025. The GPhC updated its guidance for pharmacist prescribers in April 2025. The GMC and GDC positions were already in place.
A pharmacist independent prescriber can prescribe within their competence, after an in-person assessment. A pharmacist supplementary prescriber cannot prescribe non-surgical cosmetic products at all. A clinic should confirm which kind of prescriber it is working with.
Sources
- General Medical Council. Good practice in prescribing and managing medicines and devices: deciding if it is safe to prescribe.
- General Medical Council. Cosmetic interventions: safety and quality, on physical examination before prescribing injectable cosmetic medicines.
- Nursing and Midwifery Council. Updating its position on remote prescribing of non-surgical cosmetic medicines, and its guidance for prescribers, effective 1 June 2025.
- General Pharmaceutical Council. In practice: Guidance for pharmacist prescribers, updated April 2025, section 4.3 on non-surgical cosmetic products.
- General Dental Council. Guidance on prescribing medicines, on remote prescribing for non-surgical cosmetic procedures.
Filed under: Regulation · Aesthetics · Nursing



